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Abstract Caspases are a family of cysteine proteases which
play a crucial role in apoptosis and inflammation. The
involvement of caspases in these processes can be demonstrated
by their irreversible inhibition with fluoromethyl ketone and
chloromethyl ketone derivatives of peptides resembling the
cleavage site of known caspase substrates. These inhibitors
irreversibly alkylate the cysteine residue in the active site of
caspases. In this study we show that a biotinylated fluoromethyl
ketone peptide inhibitor of caspases (z-VAD.fmk) also efficiently
affinity-labeled cathepsin B and cathepsin H. In addition, the
caspase inhibitors z-VAD.fmk, z-DEVD.fmk and Ac-
YVAD.cmk also efficiently inhibited cathepsin B activity in
vitro and in tissue culture cells at concentrations that are
generally used to demonstrate the involvement of caspases.
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1. Introduction
In recent years, programmed cell death or apoptosis has
been studied intensively. The main ‘executioners’ of apoptosis
seem to be caspases which are cysteine proteases that specif-
ically cleave their substrate after an aspartate residue (for re-
view see [1]). Caspases reside in the cell as inactive proforms,
which are proteolytically converted into their active forms by
autoprocessing or by other caspases. Active caspases then
cleave speci¢c substrates that need to be activated or inacti-
vated during the process of apoptosis [1]. In addition, speci¢c
members of the caspase family are also involved in the matu-
ration of proin£ammatory cytokines such as prointerleukin-1L
(proIL-1L), and are therefore important mediators of in£am-
mation [2].
A helpful tool to elucidate the role of caspases in apoptosis
and the maturation of cytokines has been so-called speci¢c
caspase peptide inhibitors that are aldehyde or £uoro/chloro-
methyl ketone derivatives of the target cleavage sequence in
the physiological substrates that were ¢rst identi¢ed. The irre-
versible caspase-1 inhibitor Ac-YVAD.cmk is based on the
target sequence in proIL-1L (YVHD) [3]. Another inhibitor,
Ac-DEVD.fmk, is derived from the cleavage site in poly-
(ADP-ribose)polymerase (PARP) and inhibits caspase-3 and
members of the caspase-3 subfamily [4]. Finally, z-VAD.fmk
has been used as a broad spectrum inhibitor of caspases. Such
compounds are able to block the release of IL-1L from human
monocytes, or to inhibit apoptosis in diverse cell types [5,6].
Caspase inhibitors such as z-VAD.fmk also import protection
in several in vivo models of acute liver diseases [7,8]. Finally,
biotinylated derivatives of these inhibitors have also been
demonstrated to be useful for a⁄nity labeling of active cas-
pases in crude cell extracts [9^11]. In a similar approach to
identify active caspases in murine liver extracts, we recently
found that the biotinylated caspase inhibitor z-VAD.fmk also
labeled cathepsin B [12]. Here we further document the non-
speci¢city of methylketone peptide inhibitors of caspases by
showing that biotinylated z-VAD.fmk could e⁄ciently label
puri¢ed cathepsin B as well as cathepsin H. Moreover, several
so-called speci¢c caspase inhibitors were found to strongly
inhibit cathepsin B activity in vitro and in cultured cells at
concentrations that are commonly used to demonstrate an
involvement of caspases.
2. Materials and methods
2.1. Cells and reagents
The murine ¢brosarcoma cell line WEHI164 (obtained from Dr.
T. Espevik, University of Trondheim, Norway) was maintained in
RPMI 1640 supplemented with 10% fetal calf serum. Recombinant
murine TNF was produced by Escherichia coli and puri¢ed to at least
99% homogeneity. The preparation used had a speci¢c activity of
1.4U108 IU/mg, as determined with the international standard
(code 88/532; National Institute for Biological Standards and Con-
trol, Potters Bar, UK). Recombinant murine caspase-1 and caspase-3
were produced in E. coli and have been described previously [12].
Puri¢ed cathepsins B, D and H from human liver, as well as z-FA.fmk
and Ac-YVAD.cmk were obtained from Calbiochem-Novabiochem
International (San Diego, CA, USA). z-DEVD.fmk, z-VAD.fmk,
biotinylated z-VAD.fmk, and z-ARR.AFC were supplied by En-
zyme Systems Products (Dublin, CA, USA). Ac-DEVD.AMC and
Ac-YVAD.AMC were from Peptide Institute (Osaka, Japan).
2.2. A⁄nity labeling with biotinylated z-VAD.fmk
500 ng puri¢ed cathepsins or caspase-1 were incubated with 1 WM
biotinylated z-VAD.fmk for 20 min at 30‡C in a total volume of 25 Wl
cell free system bu¡er (10 mM HEPES-NaOH pH 7.4, 220 mM man-
nitol, 68 mM sucrose, 2 mM NaCl, 2.5 mM KH2PO4, 0.5 mM
EGTA, 2 mM MgCl2, 5 mM pyruvate, 0.1 mM PMSF and 1 mM
dithiothreitol). Proteins were separated by SDS-PAGE and trans-
ferred to nitrocellulose membranes which were then incubated with
streptavidin-conjugated horseradish peroxidase (1/500). The a⁄nity-
labeled proteins were visualized by ECL (Amersham Life Science,
Amersham, UK).
2.3. Measurement of caspase and cathepsin B activity
25 ng puri¢ed caspases or cathepsin B were incubated for 1 h at
30‡C in cell free system bu¡er with 50 WM of the £uorogenic caspase
substrates Ac-DEVD.AMC or Ac-YVAD.AMC, or the £uorogenic
cathepsin B substrate z-ARR.AFC, respectively. In the case of inhib-
itor studies, enzymes were preincubated for 30 min at room temper-
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ature with a serial dilution of the inhibitors. The release of 7-amino-
4-methyl coumarin (AMC) was continuously monitored during 60 min
in a £uorometer (CytoFluor; PerSeptive Biosystems, Cambridge, MA,
USA) at an excitation wavelength of 360 nm and an emission wave-
length of 460 nm. Free 7-amino-4-tri£uoromethyl coumarin (AFC)
was monitored at an excitation wavelength of 409 nm and an emission
wavelength of 505 nm. Data are expressed as increase in £uorescence
as a function of time (vF/min). To determine cathepsin B activity in
total cell extracts, cells were lysed in 10 mM Tris-HCl pH 7, 1% NP-
40, 200 mM NaCl, 5 mM EDTA, 1 mM PMSF. Cleared cell extracts
(25 Wg cellular protein) were incubated for 1 h at 30‡C in cell free
system bu¡er with 50 WM of the £uorogenic cathepsin B substrate
z-ARR.AFC as described above.
2.4. Apoptosis assay
WEHI164 cells were seeded at 3U105 cells/ml in a 6-well plate in a
total volume of 5 ml. Cells were stimulated with TNF (1000 IU/ml)
for 6 h in the presence of actinomycin D (1 Wg/ml). The latter was
added to enhance the TNF sensitivity of the cells as described pre-
viously [13]. At the end of the incubation period, adherent cells were
trypsinized and combined with cells that were freely £oating in the
medium. Cell death was determined by trypan blue staining.
3. Results
3.1. A⁄nity labeling of cathepsins with biotinylated
z-VAD.fmk
A⁄nity labeling with biotinylated irreversible caspase inhib-
itors has been shown to be useful for detecting active caspases
in cell extracts by means of Western blotting [9^11]. Active
caspases can then be visualized on a Western blot with strep-
tavidin-conjugated peroxidase. In a similar approach with the
biotinylated caspase inhibitor z-VAD.fmk and murine liver
extracts, we could recently demonstrate the speci¢c labeling
of a number of proteins that could be visualized as four dis-
crete bands [12]. Surprisingly, upon microsequencing of these
labeled proteins they turned out to correspond to cathepsins B
and H. These proteases are totally unrelated to caspases, ex-
cept for being both cysteine proteases. Because the cathepsin
family consists not only of cysteine proteases, but also of
serine and aspartic acid proteases, we analyzed whether bio-
tinylated z-VAD.fmk could also label the serine protease cath-
epsin D. Therefore, puri¢ed cathepsins B, H and D were in-
cubated with 1 WM biotinylated z-VAD.fmk and analyzed for
binding by SDS-PAGE and Western blotting. Puri¢ed cas-
pase-1 was included as a positive control. As expected, both
caspase-1 and the cysteine proteases cathepsins B and H were
clearly labeled with biotinylated z-VAD.fmk (Fig. 1, upper
panel). In contrast, labeling of the serine protease cathepsin
D could not be detected. According to their size and the
corresponding Coomassie blue gel staining of the puri¢ed
preparations (Fig. 1, lower panel), the labeled bands are likely
to correspond to the p20 subunit of caspase-1 (indicated as 1)
and speci¢c processing products of cathepsins. This was fur-
ther con¢rmed by immunoblot detection with speci¢c anti-
bodies raised against caspase-1 and cathepsin B, respectively
(data not shown). In the case of cathepsin B, z-VAD.fmk
speci¢cally labeled the intermediate form of cathepsin B lack-
ing its prodomain (indicated as 5), whereas in the case of
cathepsin H speci¢c labeling of the heavy chain was observed
(indicated as 9). The lower migrating bands which are not
labeled by biotinylated z-VAD.fmk correspond to further
processing products of cathepsins as indicated in the legend
to Fig. 1. The above results clearly demonstrate non-speci¢c
binding of the caspase inhibitor z-VAD.fmk to non-related
cysteine proteases belonging to the cathepsin family.
3.2. Inhibition of cathepsin B by caspase peptide inhibitors
The aspeci¢c labeling of cathepsins B and H with biotinyl-
ated z-VAD.fmk prompted us to analyze whether this bind-
ing also led to an inhibition of enzyme activity. Therefore,
puri¢ed cathepsin B was preincubated with 1 WM z-VAD.fmk
and analyzed for cathepsin B activity on the £uorogenic sub-
strate z-ARR.AFC. The cathepsin B inhibitor z-FA.fmk was
used as a positive control. Indeed, z-VAD.fmk completely
inhibited the activity of cathepsin B (Fig. 2A). Similarly, pre-
incubation with z-DEVD.fmk, which has been generally used
as a speci¢c inhibitor of caspases of the caspase-3 subfamily,
led to a complete inhibition of cathepsin B activity. In con-
trast, preincubation with the caspase-1 inhibitor Ac-
YVAD.cmk had no e¡ect. However, a partial inhibition of
cathepsin B activity could be observed at 100 WM (data not
shown). Our results clearly demonstrate that methyl ketone
peptide inhibitors of caspases, at concentrations which are
generally used to demonstrate the involvement of caspases,
can also inhibit cathepsin B.
To further demonstrate this non-speci¢c inhibition of cath-
epsins by methyl ketone inhibitors of caspases, we analyzed
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Fig. 1. A⁄nity labeling of cathepsins with biotinylated z-VAD.fmk
(upper panel) and Coomassie blue gel staining of the puri¢ed pro-
teases used for labeling (lower panel). 500 ng puri¢ed caspase-1,
cathepsin B, cathepsin D, or cathepsin H were incubated with 1 WM
biotin-VAD.fmk. Proteins were separated by SDS-PAGE and a⁄n-
ity-labeled proteins were revealed as described in Section 2. For
Coomassie blue detection, 4 Wg of each protease was loaded on a
separate gel. In the case of caspase-1 the labeled polypeptide corre-
sponds to the p20 subunit (band 1 in the lower panel), whereas the
labeled cathepsin polypeptides correspond to cathepsin B without
prodomain (band 5 in the lower panel) and the heavy chain of cath-
epsin H (band 9 in the lower panel), respectively. The other Coo-
massie blue-stained bands that are not labeled correspond to the
heavy chain of cathepsin B with and without a short linker region
(bands 2 and 3), the light chain of cathepsin B (band 4), and the
heavy (band 6) and light chains with or without a linker region
(bands 7 and 8) of cathepsin D. The light chain of cathepsin H
runs in the migration front of the gel and is therefore not detect-
able.
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the e¡ect of z-VAD.fmk on cathepsin B activity in WEHI164
cells. We used an inhibitor concentration of 50 WM because
this concentration has been used previously in many cellular
studies investigating the role of caspases. Pretreatment of
WEHI164 cells with the cathepsin B inhibitor z-FA.fmk as
well as with the caspase inhibitor z-VAD.fmk completely in-
hibited cathepsin B activity that could be measured in cell
extracts with the £uorogenic substrate z-ARR.AFC (Fig.
2B). Comparable results were obtained with Ac-DEVD.fmk
and when analyzed on several other cell lines (data not
shown). Therefore, we can conclude that treatment of cells
with so-called speci¢c caspase inhibitors at concentrations
that have been commonly used might also non-speci¢cally
inhibit cathepsin B and related proteases.
3.3. Caspase peptide substrates are not cleaved by cathepsin B
Similar to the processing of the £uorogenic substrate z-
ARR.AFC by cathepsin B, caspase activity can be measured
on £uorogenic substrates such as Ac-YVAD.AMC and Ac-
DEVD.AMC. In view of the above described inhibition of
cathepsin B with the corresponding methyl ketone peptide
inhibitors, we tested whether puri¢ed cathepsin B had any
activity on these substrates. As a positive control we analyzed
their processing by puri¢ed caspase-1 and caspase-3, while the
activity of cathepsin B was also tested on z-ARR.AFC. As
expected, caspase-1 preferentially cleaved Ac-YVAD.AMC,
whereas caspase-3 speci¢cally cleaved Ac-DEVD.AMC (Fig.
3). In addition, cathepsin B was clearly active on z-ARR.
AFC, but did not cleave signi¢cant amounts of the caspase
substrates. Thus, although cathepsin B can be fully inhibited
by z-DEVD.fmk, it cannot cleave the corresponding substrate
Ac-DEVD.AMC to a signi¢cant level.
3.4. The protective e¡ect of z-VAD.fmk on TNF-induced
apoptosis of WEHI164 cells is not due to cathepsin B
inhibition
Pretreatment of cells with the caspase inhibitor z-VAD.fmk
or z-DEVD.fmk can protect many cell lines against TNF-in-
duced apoptosis [14,15]. The most likely explanation for this is
of course the inhibition of caspases that are involved in the
apoptotic process. However, in view of the non-speci¢c inhi-
bition of cathepsin B by these inhibitors one cannot exclude a
role for cathepsin B as well. The more because cathepsin B
has already been implicated in some apoptotic models and in
a number of in£ammatory diseases [16,17]. Therefore we com-
pared the e¡ect of pretreatment of the cells with 50 WM of the
caspase inhibitor z-VAD.fmk or the cathepsin B inhibitor z-
FA.fmk on TNF-induced apoptosis of WEHI164 cells. Con-
trol experiments demonstrated that cathepsin B activity was
completely inhibited under these conditions (Fig. 2A). Co-
treatment with the transcription inhibitor actinomycin D
was used as a TNF-sensitizing agent [13]. Whereas z-
FEBS 21384 4-1-99
Fig. 3. E¡ect of puri¢ed caspases and cathepsin B on £uorogenic
peptide substrates. 25 ng puri¢ed caspase-1, caspase-3, or cathepsin
B were analysed for their proteolytic activity on Ac-YVAD.AMC,
Ac-DEVD.AMC, and z-ARR.AFC as described in Section 2. The
increase in £uorescence as a function of time (vF/min) was used as
a parameter for the amount of AMC or AFC that was released.
Results are representative of multiple experiments with standard de-
viations less than 10% (n = 3). An asterisk means that there was no
detectable activity present.
Fig. 2. E¡ect of chloro/£uoromethyl ketone peptide inhibitors on
the activity of cathepsin B in vitro and in tissue culture cells. A:
Puri¢ed cathepsin B (25 ng) was preincubated for 30 min with the
indicated inhibitors (1 WM), and its activity was measured with the
£uorogenic substrate z-ARR.AFC as described in Section 2. Data
are expressed as increase in £uorescence as a function of time (vF/
min). DMSO which was used as a solvent for the inhibitors served
as a negative control. Results are representative of at least three in-
dependent experiments with standard deviations less than 10%
(n = 3). An asterisk means that there was no detectable activity
present. B: WEHI164 cells were treated for 6 h with the indicated
inhibitors (50 WM), and cathepsin B activity in cell extracts was
measured as described in A. Results are representative of three inde-
pendent experiments with standard deviations less than 10% (n = 3).
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VAD.fmk considerably protected the cells from TNF-induced
cell death, z-FA.fmk had no e¡ect (Fig. 4). Similar results
were obtained with the T cell hybridoma cell line PC60
(data not shown). These results demonstrate that, at least in
the cells studied, z-VAD.fmk does not prevent TNF-induced
apoptosis by inhibiting cathepsin B.
4. Discussion
Chloro/£uoromethyl ketone peptide inhibitors of caspases
are being widely used in experiments that measure cytokine
release or apoptosis [1,2,14,18]. Compounds such as Ac-
YVAD.cmk, z-DEVD-fmk or z-VAD.fmk are believed to be
speci¢c inhibitors of caspases, but their inhibition potential is
di¡erent for several members of the caspase family. In the
present paper we show that they can also potently bind and
inhibit cysteine proteases of the cathepsin family. Most im-
portant, this already occurs at concentrations that are com-
monly used to reveal a role of caspases. Indeed, inhibitor
concentrations of 50 WM, which completely inhibit cathepsin
B, have been used in many cellular studies on apoptosis or
in£ammation [14,15,19,20]. The reason for this non-speci¢c
inhibition is still unclear. The secondary and quaternary struc-
tures of caspases do not resemble those of cathepsin B [21,22].
In addition, the active site catalytic machinery of caspases
consists of a cysteine-histidine catalytic dyad, which is di¡er-
ent from the cysteine-histidine-asparagine triad of cathepsin
B. However, the catalytic cysteine residue thiolate is an acti-
vated nucleophile which is known to be very reactive with fmk
and cmk groups [23]. Nevertheless, inhibition of cathepsin B
with chloro/£uoromethyl ketone peptide inhibitors is not sole-
ly mediated by the reactivity of the methyl ketone group, as
no inhibitory e¡ect could be observed with the related inhib-
itor z-AAD.fmk (data not shown). Therefore, the peptide part
of the inhibitor also seems to be involved in the inhibition of
cathepsin B. In contrast to caspases, which require an aspartic
acid residue at the P1 site, cathepsin B is known to have a
much broader substrate speci¢city. This £exibility might also
explain its sensitivity to caspase inhibitors as has been ob-
served in our study. Whatever the reason for the non-speci¢c
inhibition of cathepsin B by these caspase inhibitors might be,
our results imply that inhibitors such as z-VAD.fmk, z-
DEVD.fmk or Ac-YVAD.cmk should be used with care.
The fact that cathepsin B has already been implicated in
some apoptotic models and in a number of in£ammatory
diseases [16,17] might complicate the interpretation of results
obtained with so-called speci¢c caspase inhibitors. Indeed, a
recent report suggested caspases as apical activators of cath-
epsin B, based on the inhibition of bile salt-induced cathepsin
B activity with the caspase inhibitors z-VAD.fmk and z-
DEVD.fmk [24]. In addition, the use of a⁄nity labeling
with biotinylated methyl ketone inhibitors as a technique to
isolate active caspases from cell extracts might be hampered
by the binding of cathepsin B or related proteases. Finally, the
inhibition of a housekeeping protease such as cathepsin B
might also limit the therapeutic use of fmk- and cmk-derived
caspase inhibitors in di¡erent diseases.
Acknowledgements: P.S. is a research fellow with the IWT; S.V.H. is
a research fellow, and P.V. and R.B. are postdoctoral research assist-
ants with the FWO-Vlaanderen. Research was supported by the
IUAP, the BOZF, the FWO-Vlaanderen, an EC Biomed 2 Grant
(BMH4-CT96-0300) and an EC-TMR Grant (ERBFMRXCT970153).
We are grateful to Ilse Vandenbrande and Marc Van de Craen for
expression and puri¢cation of caspases.
References
[1] Thornberry, N.A. and Lazebnik, Y. (1998) Science 281, 1312^
1316.
[2] Wang, S., Miura, M., Jung, Y., Zhu, H., Li, E. and Yuan, J.
(1998) Cell 92, 501^509.
[3] Rano, T., Timkey, T., Peterson, E., Rotonda, J., Nicholson, D.,
Becker, J., Chapman, K. and Thornberry, N. (1997) Chem. Biol.
4, 149^155.
[4] Lazebnik, Y., Kaufmann, S., Desnoyers, S., Poirier, G. and
Earnshaw, W. (1994) Nature 371, 346^347.
[5] Cohen, M. (1997) Biochem. J. 326, 1^16.
[6] Villa, P., Kaufmann, S. and Earnshaw, W. (1997) Trends Bio-
chem. Sci. 22, 388^393.
[7] Rodriguez, I., Matsuura, K., Ody, C., Nagata, S. and Vassalli, P.
(1996) J. Exp. Med. 184, 2067^2072.
[8] Kuºnstle, G., Leist, L., Uhlig, S., Revesz, L., Feifel, R., Mac-
Kenzie, A. and Wendel, A. (1997) Immunol. Lett. 55, 5^10.
[9] Takahashi, A., Hirata, H., Yonehara, S., Imai, Y., Lee, K.,
Moyer, R., Turner, P., Mesner, P., Okazaki, T., Sawai, H., Kishi,
S., Yamamoto, K., Okuma, M. and Sasada, M. (1997) Oncogene
14, 2741^2752.
[10] Faleiro, L., Kobayashi, R., Fearnhead, H. and Lazebnik, Y.
(1997) EMBO J. 16, 2271^2281.
[11] Martins, L.M., Kottke, T., Mesner, P.W., Basi, Q.S., Sinha,
S., Frigon Jr., N., Tatar, E., Tung, J.S., Bryant, K., Takahashi,
A., Svingen, P.A., Madden, B.J., McCormick, D.J., Earnshaw,
W.C. and Kaufmann, S.H. (1997) J. Biol. Chem. 272, 7421^
7430.
[12] Schotte, P., Van Criekinge, W., Van de Craen, M., Van Loo, G.,
Desmedt, M., Grooten, J., Cornelissen, M., De Ridder, L., Van-
dekerckhove, J., Fiers, W., Vandenabeele, P. and Beyaert, R.
(1998) Biochem. Biophys. Res. Commun. 251, 379^387.
[13] Lasek, W., Giermasz, A., Kuc, K., Wankowicz, A., Feleszko, W.,
Golab, J., Zagozdzon, R., Stoklosa, T. and Jakobisiak, M. (1996)
Int. J. Cancer 66, 374^379.
[14] Haviv, R. and Stein, R. (1998) J. Neurosci. Res. 52, 380^389.
[15] Vercammen, D., Beyaert, R., Denecker, G., Goossens, V., Van
Loo, G., Declercq, W., Grooten, J., Fiers, W. and Vandenabeele,
P. (1998) J. Exp. Med. 187, 1477^1485.
[16] Mort, J. and Buttle, D. (1997) Int. J. Biochem. Cell. Biol. 29,
715^720.
[17] Guenette, R., Mooibroek, M., Wong, K., Wong, P. and Tennis-
wood, M. (1994) Eur. J. Biochem. 226, 311^321.
FEBS 21384 4-1-99
Fig. 4. Comparison of the e¡ect of z-VAD.fmk and z-FA.fmk on
TNF-induced apoptosis of WEHI164 cells. Cells were pretreated for
1 h with 50 WM z-VAD.fmk or z-FA.fmk, and subsequently treated
for 6 h with 1000 IU/ml TNF in the presence of 1 Wg/ml actinomy-
cine D. DMSO which was used as a solvent for the inhibitors
served as a negative control. Cell death was analyzed by counting
the number of trypan blue positive cells.
P. Schotte et al./FEBS Letters 442 (1999) 117^121120
[18] Zhang, Y., Center, D., Wu, D., Cruikshank, W., Yuan, J., An-
drews, D. and Kornfeld, H. (1998) J. Biol. Chem. 273, 1144^
1149.
[19] Fulda, S., Friesen, C., Los, M., Sca⁄di, C., Mier, W., Benedict,
M., Nunez, G., Krammer, P., Peter, M. and Debatin, K. (1997)
Cancer Res. 57, 4956^4964.
[20] Hilbi, H., Chen, Y., Thirumalai, K. and Zychlinsky, A. (1997)
Infect. Immun. 65, 5165^5170.
[21] Chou, K., Jones, D. and Heinrikson, R. (1997) FEBS Lett. 419,
49^54.
[22] Podobnik, M., Kuhelj, R., Turk, V. and Turk, D. (1997) J. Mol.
Biol. 271, 774^788.
[23] Shaw, E., Angliker, H., Rauber, P., Walker, B. and Wikstrom, P.
(1986) Biomed. Biochim. Acta 45, 1397^1403.
[24] Jones, B., Roberts, P., Faubion, W., Kominami, E. and Gores,
G. (1998) Am. J. Physiol. 275, 723^730.
FEBS 21384 4-1-99
P. Schotte et al./FEBS Letters 442 (1999) 117^121 121
